Guaranteed SEO Boost: Triple Your Rankings with Backlinks starting at 5$
Written by Business News » Updated on: October 23rd, 2024
IMARC Group, a leading market research company, has recently released a report titled "Drug-Eluting Stents Market Report by Coating (Polymer Based Coating, Polymer Free Coating), Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, and Others), Stent Platform (Stainless-steel, Cobalt-Chromium, Platinum-Chromium, Nitinol, and Others), Generation (1st Generation, 2nd Generation, 3rd Generation, 4th Generation), Application (Coronary Artery Disease, Peripheral Artery Disease), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Region 2024-2032". The study provides a detailed analysis of the industry, including the drug-eluting stents market trends, size, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
The global drug-eluting stents market size reached US$ 8.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.51% during 2024-2032.
Request to Get the Sample Report: https://www.imarcgroup.com/drug-eluting-stents-market/requestsample
Factors Affecting the Growth of the Drug-Eluting Stents Industry:
Rising prevalence of cardiovascular diseases (CVDs):
CVDs, including coronary artery disease, are the leading causes of morbidity and mortality worldwide. Factors such as an aging global population, unhealthy lifestyles, poor diet, physical inactivity, and high prevalence of risk factors like hypertension, diabetes, and smoking contribute to the increasing incidence of CVDs. According to the World Health Organization (WHO), CVDs account for nearly 17.9 million deaths annually, representing 31% of all global deaths. As the number of patients requiring interventional cardiology procedures grows, the demand for effective treatments like drug-eluting stents, which prevent restenosis and improve long-term outcomes, is bolstering the market growth.
Advancements in stent technology:
Early-generation stents faced issues such as late stent thrombosis and restenosis, which limited their widespread adoption. However, significant research and development (R&D) efforts have led to the introduction of a new-generation data encryption standard (DES) with improved safety and efficacy profiles. Innovations such as biodegradable polymers, which gradually dissolve after delivering the drug, have reduced the risk of late stent thrombosis. Furthermore, the development of more biocompatible materials and drugs that minimize inflammatory responses and promote better endothelialization has enhanced the overall performance of DES. These advancements have led to higher acceptance and preference for DES among cardiologists and patients, impelling the market reach.
Increasing adoption of minimally invasive surgical procedures:
Minimally invasive techniques, such as percutaneous coronary interventions (PCI), offer several advantages over traditional open-heart surgeries, including shorter recovery times, reduced hospital stays, and lower procedural risks. DES plays a critical role in these procedures by providing a reliable solution for revascularizing blocked coronary arteries without the need for extensive surgery. As patients and healthcare providers seek safer and more efficient treatment options, the preference for minimally invasive procedures, and consequently DES, has risen. Furthermore, the growing awareness of the benefits of these procedures, coupled with the increasing availability of specialized cardiac catheterization labs and trained interventional cardiologists, is contributing to the market growth.
Drug-Eluting Stents Market Report Segmentation:
By Coating:
Polymer-free coating accounts for the majority of shares because it reduces the risk of late stent thrombosis and improves biocompatibility.
By Drug:
On the basis of drugs, the market is segmented into sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, and others.
By Stent Platform:
Cobalt-chromium dominates the market due to its superior strength and flexibility with thinner struts, enhancing procedural outcomes.
By Generation:
Based on the generation, the market is classified into 1st generation, 2nd generation, 3rd generation, and 4th generation.
By Application:
Coronary artery disease represents the largest segment because they are the most prevalent cardiovascular condition requiring stent implantation.
By End-user:
Hospital dominates the market due to interventional cardiology procedures, including stent placements.
Regional Insights:
North America enjoys the leading position owing to the advanced healthcare infrastructure, high healthcare expenditure, and a significant patient population with cardiovascular diseases.
Global Drug-Eluting Stents Market Trends:
The expanding healthcare infrastructure, increasing healthcare expenditure, and the growing focus on preventive healthcare measures, which collectively enhance access to advanced cardiovascular treatments and promote the use of innovative medical devices like drug-eluting stents, are supporting the market expansion. Besides this, the rising number of clinical trials demonstrating their long-term efficacy, increased patient awareness of advanced treatment options, and supportive government policies and funding for innovative cardiovascular therapies are aiding the market growth. Furthermore, the integration of artificial intelligence (AI) in diagnostic cardiology, enabling precise stent placement, and the growing prevalence of chronic lifestyle diseases like obesity, which heightens the need for advanced cardiovascular interventions, is strengthening the market reach.
Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=4815&flag=C
Top Companies Operated in Drug-Eluting Stents Industry:
Key Highlights of the Report:
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
We do not claim ownership of any content, links or images featured on this post unless explicitly stated. If you believe any content or images infringes on your copyright, please contact us immediately for removal ([email protected]). Please note that content published under our account may be sponsored or contributed by guest authors. We assume no responsibility for the accuracy or originality of such content. We hold no responsibilty of content and images published as ours is a publishers platform. Mail us for any query and we will remove that content/image immediately.
Copyright © 2024 IndiBlogHub.com. Hosted on Digital Ocean